Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR
Conditions
Interventions
ABT-806
Locations
3
United States
Site Reference ID/Investigator# 54056
Baltimore, Maryland, United States
Site Reference ID/Investigator# 41931
Boston, Massachusetts, United States
Site Reference ID/Investigator# 43422
Tacoma, Washington, United States
Start Date
November 1, 2010
Primary Completion Date
November 1, 2012
Completion Date
November 1, 2012
Last Updated
November 21, 2017
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions